Small molecule screens reveal new class of anticancer compounds
Two screening techniques were used by researchers to find anticancer compounds that target the aryl hydrocarbon receptor.
List view / Grid view
Two screening techniques were used by researchers to find anticancer compounds that target the aryl hydrocarbon receptor.
Researchers have shown that topoisomerase TOP2A eliminates negative supercoiling, causing an increase in the number of turns of DNA strands and impacting gene expression.
Epithelial cell communication depends on the side of the cell, which could have implications for understanding how cancer spreads.
A combination of computer simulations and fragment screening have uncovered 27 molecular binding sites on tubulin, a protein of the cell cytoskeleton.
According to new research, the biochip market will grow as a result of the rising demand for personalised medicine.
Researchers have shown how the MIS hormone can prevent ovulation in females, making it a potential new form of contraception.
Researchers have shown that Chroman 1, Emricasan and trans-ISRIB, in combination with polyamines, are effective at protecting induced pluripotent stem cells from stress.
The exciting potential of immunotherapy for cancer treatment continues its exploration and here, Drug Target Review investigates three of the latest pre-clinical developments in immuno-oncology research.
A new study in cell cultures has shown that the sanguinarine plant compound could be used to treat people with triple-negative breast cancer.
Having synthesised the curcusone D compound, researchers demonstrated its promise as the first BRAT1 inhibitor, making it a potential cancer therapy.
A range of imaging and computational techniques were used by researchers to discover the structure of the PH domain of PLEKHA7.
Scientists have created an assay to detect the protein cathepsin B in blood, a biomarker for a range of diseases.
Researchers say that inhibiting NLRP3 with Dapansutrile could be an effective strategy to prevent melanoma tumour growth.
Scientists have shown that culturing cells with a modified serum could allow drugs to be screened for toxicity earlier during research.
Researchers have elucidated the 3D structure of the Taspase 1 enzyme, known to be involved in a range of cancers.